4'-乙烯基-2'-脱氧化 (EdC) 通过诱导复制性压力优先准淋巴瘤和白血病亚型
Marissa L Calbert1,2, Gurushankar Chandramouly1, Clare M Adams3
1Department of Biochemistry and Molecular Biology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Molecular cancer therapeutics
|December 8, 2023
概括
一种新型的抗癌核酸,4'-乙氨基-2'-脱氧胺 (EdC),对扩散性大B细胞淋巴瘤 (DLBCL) 和急性淋巴细胞白血病 (ALL) 具有强烈的活性,克服了常见的抵抗机制.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 抗癌核化物对于治疗固体瘤和血液恶性瘤至关重要.
- 对核酸代谢的耐药性在癌症治疗中构成了重大挑战.
研究的目的:
- 发现抗癌新型核酸前药物,有效对抗血液性恶性瘤.
- 描述一种新发现的化合物的作用机制和抗性概况.
主要方法:
- 核酸特异性多重化高通量选. 核酸特异性多重化高通量选.
- 生物化学试验以确定酶依赖性 (脱氧丁酶).
- 基于细胞的测试用于细胞周期分析和DNA复制.
- 确定与EDC结合的脱氧基丁激酶的晶结构 (2.1Å).
- 在DLBCL和B-ALL模型中的体内疗效研究.
主要成果:
- 发现4 - 乙烯基-2 - 脱氧基提丁 (EdC) 是一种强大的抗癌核酸盐.
- EdC对扩散型大B细胞淋巴瘤 (DLBCL) 和急性淋巴细胞白血病 (ALL) 具有优先活性.
- EdC充当链终结器,诱导复制分叉停止和S相积累,依赖于脱氧基因酶 (DCK) 酸化.
- 埃德克表现出对cytidine去胺和SAMHD1代谢的抗性.
- 与尼拉拉相比,EDC对ALL的效果优于nelarabine,并且在体内对DLBCL和B-ALL的高疗效.
结论:
- EdC是一种有前途的第三代抗癌核酸原药.
- EdC克服了关键的核酸耐药机制.
- 埃德克是治疗DLBCL和ALL的潜在临床前候选人.
相关概念视频
S-Cdk Initiates DNA Replication
4.7K
The cell cycle is a series of events leading to DNA duplication followed by the division of cell content to form two daughter cells. The cell cycle progresses in four stages—the cell increases in size (gap 1 or G1-phase), duplicates its DNA (synthesis or S-phase), prepares to divide (gap 2 or G2-phase), and divides (mitosis or M-phase).
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
4.7K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The DNA Replication Fork
36.0K
An organism’s genome needs to be duplicated in an efficient and error-free manner for its growth and survival. The replication fork is a Y-shaped active region where two strands of DNA are separated and replicated continuously. The coupling of DNA unzipping and complementary strand synthesis is a characteristic feature of a replication fork. Organisms with small circular DNA, such as E. coli, often have a single origin of replication; therefore, they have only two replication...
36.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


